Printer Friendly

Dermatological Drugs: World Market Prospects 2012-2022.

NEW YORK, May 2, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Dermatological Drugs: World Market Prospects 2012-2022

http://www.reportlinker.com/p0788690/Dermatological-Drugs-World-Market-Prospects-2012-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Report Details

Where are dermatological treatments heading? Visiongain's report shows you potential revenues to 2022, with data, forecasts and discussions.

This study assesses drugs to treat human skin disorders. You discover sales predictions at world market, therapeutic submarket, product and national levels to 2022.

How will 24 leading drugs - Valtrex, Zovirax, Protopic, Enbrel and others - perform from 2012? Our report gives you business research and analysis with many sales forecasts.

Also, you see forecasting of five derma submarkets to 2022, finding potential revenues:

-- Dermatitis

-- Psoriasis

-- Acne

-- Infectious skin diseases

-- Miscellaneous dermatologics.

What does the future hold? The pharma industry has potential for improved treatments and increased revenues from dermatological agents. The R&D pipeline is strong.

Our report discusses GSK, Galderma, Amgen, Abbott, J&J and other pharmaceutical companies, assessing prospects of the industry and market.

Many commercial opportunities in treating skin disorders remain, including increased revenues. You can investigate the future of that area now.

Visiongain's study provides data, analysis and opinion aiming to benefit your research, calculations, meetings and presentations. You find answers in our work.

Revenue forecasts, market shares, developmental trends and discussions

In our report you find revenue forecasting, growth rates and market shares. Also, you have qualitative analyses (including SWOT) and discussion of R&D activities. You receive 121 tables and charts and a research interview.

Advantages of Dermatological Drugs: World Market Prospects 2012-2022 for your work

In particular, this study gives you the following knowledge on the topic:

-- Find potential revenues to 2022 for the world market and submarkets

-- Discover revenue forecasts to 2022 for 24 leading products

-- See market forecasting to 2022 for the US, Japan, the EU5, China and India

-- Assess leading companies, discovering activities and outlooks

-- Review R&D, seeing pipeline trends

-- Investigate competition and opportunities influencing sales

-- Find out what will stimulate and restrain the industry and market

-- View opinion from the sector, receiving primary research.

There, you find a distinctive mix of quantitative and qualitative analyses with independent predictions. Without our report, you could miss out on information that your competitors are using.

We investigate commercial applications of dermatology, helping you to stay ahead.

Gain business research and analysis for the treatment of skin disorders

Our study is for everybody needing industry and market analyses for dermatological drugs. Find data, trends and answers. Avoid missing out - please order our report now.

Visiongain is a trading partner with the US Federal Government

CCR Ref number: KD4R6

Table of Contents

1. Executive Summary

1.1 World Dermatological Drug Market: Overview of Findings

1.2 Aims, Scope and Format of the Report

1.3 Research and Analysis Methods

2. Introduction to Dermatological Disorders and Their Treatments

2.1 An Introduction to Dermatology

2.1.1 The Structure of the Skin

2.1.2 Hair

2.1.3 Nails

2.1.4 Sweat and Sebaceous Glands

2.2 Functions of the Skin

2.2.1 Protection

2.2.2 Sensation

2.2.3 Vitamin D Synthesis

2.2.4 Temperature Regulation and Heat Insulation

2.2.5 Storage

2.2.6 Prevention of Water Loss

2.3 Common Skin Diseases

2.4 An Introduction to Acne Vulgaris

2.4.1 Acne Conglobata

2.4.2 Acne Fulminans

2.4.3 Gram-Negative Folliculitis

2.4.4 Pyoderma Faciale

2.4.5 Causes of Acne

2.5 An Introduction to Dermatitis

2.5.1 Atopic Dermatitis

2.5.2 Contact Dermatitis

2.5.3 Seborrheic Dermatitis

2.5.4 Nummular Dermatitis

2.5.5 Perioral Dermatitis

2.6 An Introduction to Psoriasis

2.6.1 Plaque Psoriasis

2.6.2 Guttate Psoriasis

2.6.3 Pustular Psoriasis

2.6.4 Inverse Psoriasis

2.6.5 Erythrodermic Psoriasis

2.7 An Introduction to Rosacea

2.7.1 Erythematotelangiectatic Rosacea

2.7.2 Papulopustular Rosacea

2.7.3 Phymatous Rosacea

2.7.4 Ocular Rosacea

2.8 An Introduction to Alopecia

2.8.1 Alopecia Areata

2.8.2 Alopecia Totalis

2.8.3 Alopecia Universalis

2.8.4 Androgenetic Alopecia

2.8.5 Alopecia Barbae

2.8.6 Alopecia Mucinosa

2.8.7 Traction Alopecia

2.8.8 Anagen Effluvium

2.8.9 Telogen Effluvium

2.9 An Introduction to Infectious Diseases of the Skin

2.9.1 Bacterial Skin Infections

2.9.1.1 Impetigo

2.9.1.2 Folliculitis

2.9.1.3 Cellulitis

2.9.1.4 Furunculosis

2.9.1.5 Carbuncle

2.9.2 Fungal Skin Infections

2.9.2.1 Tinea Pedis (Athlete's Foot)

2.9.2.2 Tinea Unguium (Ringworm of the Nails)

2.9.2.3 Tinea Corporis (Ringworm of the Skin)

2.9.2.4 Tinea Capitis (Scalp Ringworm)

2.9.2.5 Kerions

2.9.3 Viral Skin Infections

2.9.3.1 Molluscum Contagiosum

2.9.3.2 Warts

2.9.3.3 Herpes Simplex

2.9.3.4 Chickenpox

2.9.3.5 Herpes Zoster

2.10 Common Skin Treatments

2.10.1 Creams and Semisolid Emulsions

2.10.2 Ointments

2.10.3 Lotions

2.10.4 Solutions

2.10.5 Occlusive Therapy

2.10.6 Cleansing Agents

2.10.7 Protecting Powders and Hydrophilic Polymer

2.10.8 Anti-Infective Agents

2.10.9 Anti-Inflammatory Agents

3. The World Dermatological Drug Market, 2012-2022

3.1 The World Dermatological Drug Market in 2010

3.2 The Infectious Skin Diseases Market Dominates the World Dermatological Drug Market

3.3 Biologic Agents for the Treatment of Psoriasis Are the Leading Drugs in the Dermatologics Market

3.4 The Changing Landscape of the Dermatological Drug Market

3.5 The World Dermatological Drug Market: Forecasts, 2012-2022

3.5.1 Market Shares of Leading Segments

3.5.1.1 The Psoriasis Market Will Achieve the Greatest Increase in Market Share

3.6 The Future of the Dermatological Drug Market

3.6.1 Blockbuster Sales - Hard to Achieve?

4. The Infectious Skin Diseases Drug Market, 2012-2022

4.1 The Infectious Skin Diseases Drug Market in 2010

4.1.1 Antiviral Products Led the Dermatological Anti-Infectives Market in 2010

4.1.2 Systemic Antiviral Products Lead the Infectious Skin Diseases Drug Market

4.2 World Infectious Skin Diseases Drug Market Forecast, 2012-2022

4.3 Valtrex (Valacyclovir)

4.3.1 Patent Expiry and the End of Blockbuster Revenues

4.3.2 Valtrex Sales Will Continue to Decline

4.4 Zovirax

4.4.1 Zovirax Sales Forecast, 2012-2022

4.5 Aldara/Zyclara (Imiquimod)

4.5.1 Patent Expiry and Other Challenges

4.5.2 Lifecycle Management

4.5.3 Aldara Sales Forecast, 2012-2022

4.6 Bactroban (Mupirocin)

4.6.1 Bactroban Sales Forecast, 2012-2022

4.7 Lamisil (Terbinafine)

4.7.1 Lamisil Sales Forecast, 2012-2022

4.8 The Infectious Skin Diseases Market - Summary

5. The Dermatitis Drug Market, 2012-2022

5.1 The Dermatitis Drug Market in 2010

5.1.1 Corticosteroids are the Leading Dermatitis Treatment

5.2 Dermatitis Drug Market Forecast, 2012-2022

5.3 Protopic (Tacrolimus)

5.3.1 Protopic Sales Forecast, 2012-2022

5.3.2 Protopic Benefits from Expanded Indication

5.3.3 Will Protopic's Strong Sales Increase Recur?

5.4 Elidel (Pimecrolimus)

5.4.1 Elidel Rights Sold

5.4.2 Regulatory Matters

5.4.3 Elidel Sales Forecast, 2012-2022

5.4.4 Expanding Elidel Indications May Stimulate Sales Growth

5.5 Elocon (Mometasone Furoate)

5.5.1 Elocon Sales Forecast, 2012-2022

5.6 Clob X/Clobex (Clobetasol Propionate)

5.6.1 Clobex Sales Increase

5.7 Soriatane (Acitretin)

5.8 The Dermatitis Drug Market - Summary

6. The Psoriasis Drug Market, 2012-2022

6.1 The Psoriasis Drug Market in 2010

6.2 Biologic Drugs Lead the Psoriasis Market

6.3 World Psoriasis Drug Market Forecast, 2012-2022

6.3.1 Growth in the Psoriasis Drug Market Will Be Spurred by Increasing Use of Biologics

6.4 Enbrel (Etanercept)

6.4.1 Enbrel Continued to Lead the Psoriasis Market in 2010

6.4.2 Enbrel Sales Forecast, 2012-2022

6.4.3 Enbrel in Competition with Humira and Stelara

6.4.4 Biosimilar Competition

6.4.5 Competition from Pipeline Products

6.5 Humira (Adalimumab)

6.5.1 Humira Has Gained Market Acceptance

6.6 Stelara (Ustekinumab)

6.6.1 Stelara Will Achieve Strong Growth in the Psoriasis Market

6.7 Remicade (Infliximab)

6.8 Topical Treatments for Psoriasis

6.9 Daivobet (Calcipotriol and Betamethasone)

6.9.1 Daivobet Leads the Topical Psoriasis Market

6.9.2 Daivobet Sales Will Grow Until 2020

6.10 Taclonex (Calcipotriol and Betamethasone)

6.10.1 Taclonex Sales Forecast, 2012-2022

6.10.2 Taclonex May Face Generic Competition

6.11 Dovonex (Calcipotriol)

6.11.1 Patent Expiration and Generic Competition

6.11.2 Dovonex Sales Forecast, 2012-2022

6.12 The World Psoriasis Drug Market - Summary

7. The Acne Drug Market, 2012-2022

7.1 Available Treatments and Unmet Needs

7.2 Leading Products in the Acne Drug Market, 2010

7.3 World Acne Drug Market Forecast, 2012-2022

7.4 Claravis (Isotretinoin)

7.4.1 Claravis Sales Forecast, 2012-2022

7.5 Solodyn (Minocycline)

7.5.1 Solodyn Led the World Acne Drug Market in 2010

7.5.2 Solodyn Sales Forecast, 2012-2022

7.6 Diane (Cyproterone and Ethinylestradiol)

7.6.1 Diane Sales Forecast, 2012-2022

7.7 Duac (Clindamycin and Benzoyl Peroxide)

7.8 Doryx (Doxycycline Hyclate)

7.8.1 Doryx Sales Forecast, 2012-2022

7.8.2 Lifecycle Management of Doryx

7.9 Differin (Adapalene)

7.9.1 Differin Sales Forecast, 2012-2022

7.9.2 Lifecycle Management of Differin

7.10 Combination Treatments for Acne

7.10.1 Epiduo (Adapalene and Benzoyl Peroxide)

7.10.2 Ziana (Tretinoin and Clindamycin)

7.10.3 Veltin (Tretinoin and Clindamycin)

7.11 The World Acne Drug Market - Summary

8. Miscellaneous Dermatological Drugs, 2012-2022

8.1 The Miscellaneous Dermatological Drugs Market in 2010

8.2 Miscellaneous Dermatological Drugs: Market Forecast, 2012-2022

8.3 Propecia (Finasteride)

8.3.1 Propecia Sales Will Fall

8.3.2 Propecia Faces Competition from Rogaine/Regaine

8.4 The Miscellaneous Dermatological Drugs Market - Summary

9. Leading Companies in the Dermatological Drug Market

9.1 Prominent Companies in the Dermatological Drug Market, 2010

9.2 GlaxoSmithKline

9.3 Galderma

9.4 Amgen

9.5 Abbott

9.6 Johnson & Johnson

9.7 Medicis Pharmaceutical

9.8 LEO Pharma

9.9 Warner Chilcott

9.10 Valeant

9.11 Roche

9.12 Sanofi

9.13 Bayer

9.14 Merck & Co.

9.15 Meda AB

9.16 Novartis

9.17 Companies in the Dermatological Drug Market - Summary

10. The R&D Pipeline for Dermatological Pharmaceuticals

10.1 The Size of the Dermatological Pharmaceuticals Market Encourages R&D

10.2 New Technology in R&D Pipeline Activities

10.2.1 Reformulation

10.2.2 Combination Treatments

10.2.3 New Mechanisms and Drug Delivery Technologies

10.3 Potential Market Entrants

10.4 The Infectious Skin Disease Pipeline

10.4.1 NB-001

10.5 The Dermatitis Pipeline

10.5.1 MRX6

10.6 The Psoriasis Pipeline

10.6.1 Briakinumab

10.6.2 Apremilast

10.6.3 AN2728

10.6.4 Tofacitinib

10.7 The Acne Pipeline

10.7.1 Visonac

10.7.2 Acne Vaccine

10.7.3 ACAT Inhibitor

10.8 The Miscellaneous Dermatological Drugs Pipeline

10.9 PEP005

10.10 Innovation Rules for Early-Stage Pipeline Drugs

11. National Market Forecasts, 2012-2022

11.1 Leading National Markets for Dermatological Drugs, 2010

11.2 Leading National Markets for Dermatological Drugs: Forecasts, 2012-2022

11.3 The Dermatological Drug Market in the US, 2012-2022

11.4 The Dermatological Drug Market in Japan, 2012-2022

11.5 The Dermatological Drug Market in Germany, 2012-2022

11.6 The Dermatological Drug Market in France, 2012-2022

11.7 The Dermatological Drug Market in the UK, 2012-2022

11.8 The Dermatological Drug Market in Italy, 2012-2022

11.9 The Dermatological Drug Market in Spain, 2012-2022

11.10 The Dermatological Drug Market in India, 2012-2022

11.11 The Dermatological Drug Market in China, 2012-2022

12. Qualitative Analysis of the World Dermatological Drug Market, 2012

12.1 SWOT Analysis

12.2 Market Drivers

12.3 Market Restraints

12.4 There is Scope for Market Development and Expansion

12.5 Advances in Research are Likely to Bring Benefits to the Market

12.6 Downward Pressures on Drug Prices Affect the Industry

12.7 Competition in the Dermatological Drug Market Will Intensify

12.8 Substitutes

12.9 How Great is the Threat from Generic Drugs in the Dermatological Sector?

13. Research Interview

13.1 Interview with Dr Adam Friedman

13.1.1 Unmet Needs in the Dermatological Drugs Marks

13.1.2 Key Areas for Dermatological Research

13.1.3 Pipeline Dermatological Drug Products

13.1.4 The Future Role of Nanotechnology in Dermatological Drugs

13.1.5 Challenges in Advancing Dermatological Treatments

14. Conclusions

14.1 The World Dermatological Drug Market Will Experience Sales Growth

14.2 Will The Infectious Skin Diseases Market Continue to Dominate the Overall Market?

14.3 Dermatological Treatments: Companies Prominent in that Industry and Market

14.4 The Need for New Therapies for the Treatment of Dermatitis

14.5 Combination Treatments and Lifecycle Management in the Acne Market

14.6 Biologics Will Drive Growth in the Psoriasis Market

14.7 Overall World Dermatological Drug Market Growth Will Continue

List of Tables

Table 3.1 The World Dermatological Drugs: Market Segments, Revenues ($m) and Market Shares (%), 2010

Table 3.2 Leading Dermatological Drugs ($m), 2010

Table 3.3 World Dermatological Drug Market: Sales Forecasts by Segment ($m), AGR (%), CAGR (%), 2010-2016

Table 3.4 World Dermatological Drug Market: Sales Forecasts by Segment ($m), AGR (%), CAGR (%), 2017-2022

Table 3.5 Segments of the World Dermatological Drug Market: Forecasts by Market Share (% of Total Revenues), Rank (By Revenue), 2010, 2016 and 2022

Table 4.1 Leading Drugs for the Treatment of Infectious Skin Diseases ($m), 2010

Table 4.2 Sales ($m) and Market Shares (%) of Infectious Skin Diseases Drugs by Class, 2010

Table 4.3 Infectious Skin Disease Drug Sales Forecasts ($m), Growth Rates (%), CAGR (%), 2010-2016

Table 4.4 Infectious Skin Disease Drug Sales Forecasts ($m), Growth Rates (%), CAGR (%), 2017-2022

Table 4.5 Valtrex Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022

Table 4.6 Zovirax Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022

Table 4.7 Aldara Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022

Table 4.8 Bactroban Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022

Table 4.9 Lamisil Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022

Table 5.1 Leading Drugs ($m) for the Treatment of Dermatitis, 2010

Table 5.2 Sales ($m) and Market Shares (%) of Dermatitis Drugs by Class, 2010

Table 5.3 Dermatitis Drug Sales Forecasts ($m), Growth Rates (%), CAGR (%), 2010-2016

Table 5.4 Dermatitis Drug Sales Forecasts ($m), Growth Rates (%), CAGR (%), 2017-2022

Table 5.5 Protopic Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022

Table 5.6 Elidel Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022

Table 5.7 Elocon Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022

Table 5.8 Clobex Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022

Table 5.9 Soriatane Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022

Table 6.1 Market Leading Drugs ($m) for the Treatment of Psoriasis, 2010

Table 6.2 Psoriasis Drug Sales Forecasts ($m), Growth Rates (%), CAGR (%), 2010-2016

Table 6.3 Psoriasis Drug Sales Forecasts ($m), Growth Rates (%), CAGR (%), 2017-2022

Table 6.4 Enbrel Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022

Table 6.5 Humira Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022

Table 6.6 Stelara Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022

Table 6.7 Remicade Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022

Table 6.8 Daivobet Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022

Table 6.9 Taclonex Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022

Table 6.10 Dovonex Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022

Table 7.1 Acne Drug Sales ($m) by Class, 2010

Table 7.2 Market Leading Drugs ($m) for the Treatment of Acne, 2010

Table 7.3 Acne Drug Sales Forecasts ($m), Growth Rates (%), CAGR (%), 2010-2016

Table 7.4 Acne Drug Sales Forecasts ($m), Growth Rates (%), CAGR (%), 2017-2022

Table 7.5 Claravis Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022

Table 7.6 Solodyn Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022

Table 7.7 Diane Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022

Table 7.8 Duac Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022

Table 7.9 Doryx Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022

Table 7.10 Differin Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022

Table 8.1 Miscellaneous Dermatological Drugs Market: Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022

Table 8.2 Propecia Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022

Table 9.1 Leading Companies in the Dermatological Drugs Market: Revenues ($m) and Market Shares (%), 2010

Table 10.1 The Infectious Skin Disease Drug Pipeline, 2011

Table 10.2 Pipeline Products for the Treatment of Dermatitis, 2011

Table 10.3 Pipeline Products for the Treatment of Psoriasis, 2011

Table 10.4 Pipeline Products for the Treatment of Acne, 2011

Table 10.5 Pipeline Products for Other Skin Conditions, 2011

Table 11.1 Sales Rankings and Market Shares (%) For Nine Leading National Markets, 2010, 2016 & 2022

Table 11.2 Dermatological Market Revenues: Growth ($m, %) of Leading National Markets, 2010-2022

Table 11.3 Dermatological Drug Market Forecasts for Nine Leading National Markets: Sales ($m), AGR (%), CAGR (%), 2010-2016

Table 11.4 Dermatological Drug Market Forecasts For Nine Leading National Markets: Sales ($m), AGR (%), CAGR (%), 2017-2022

Table 11.5 US: Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022

Table 11.6 Japan: Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022

Table 11.7 Germany: Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022

Table 11.8 France: Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022

Table 11.9 UK: Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022

Table 11.10 Italy: Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022

Table 11.11 Spain: Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022

Table 11.12 India: Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022

Table 11.13 China: Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022

Table 12.1 SWOT Analysis of the Dermatological Drug Market, 2012

List of Figures

Figure 3.1 Dermatological Drug Market Shares (%) by Segment, 2010

Figure 3.2 The World Dermatological Drug Market: Sales Forecast ($m), 2010-2022

Figure 3.3 Sales Forecasts ($m) for Segments of the World Dermatological Drug Market, 2010-2022

Figure 4.1 Leading Infectious Skin Disease Drug Market Shares (%), 2010

Figure 4.2 World Infectious Skin Disease Drug Market Forecast ($m), 2010-2022

Figure 4.3 Leading Infectious Skin Disease Drugs: Market Share Forecast s (%), 2010-2022

Figure 4.4 Leading Infectious Skin Disease Drugs: Sales Forecasts ($m), 2010-2022

Figure 4.5 Valtrex Sales Forecast ($m), 2010-2022

Figure 4.6 Zovirax Sales Forecast ($m), 2010-2022

Figure 4.7 Aldara Sales Forecast ($m), 2010-2022

Figure 4.8 Bactroban Sales Forecast ($m), 2010-2022

Figure 4.9 Lamisil Sales Forecast ($m), 2010-2022

Figure 5.1 Leading Dermatitis Drugs: Market Shares (%), 2010

Figure 5.2 Leading Dermatitis Drugs: Sales Forecasts ($m), 2010-2022

Figure 5.3 Leading Dermatitis Drugs: Market Share Forecasts (%), 2010-2022

Figure 5.4 Protopic Sales Forecast ($m), 2010-2022

Figure 5.5 Elidel Sales Forecast ($m), 2010-2022

Figure 5.6 Elocon Sales Forecast ($m), 2010-2022

Figure 5.7 Clobex Sales Forecast ($m), 2010-2022

Figure 5.8 Soriatane Sales Forecast ($m), 2010-2022

Figure 6.1 Leading Psoriasis Drugs: Market Shares (%), 2010

Figure 6.2 World Psoriasis Drug Market Forecast ($m), 2010-2022

Figure 6.3 Leading Psoriasis Drugs: Sales Forecasts ($m), 2010-2022

Figure 6.4 Leading Psoriasis Drugs: Market Share Forecasts (%), 2010-2022

Figure 6.5 Enbrel Sales Forecast ($m), 2010-2022

Figure 6.6 Humira Sales Forecast ($m), 2010-2022

Figure 6.7 Stelara Sales Forecast ($m), 2010-2022

Figure 6.8 Remicade Sales Forecast ($m), 2010-2022

Figure 6.9 Daivobet Sales Forecast ($m), 2010-2022

Figure 6.10 Taclonex Sales Forecast ($m), 2010-2022

Figure 6.11 Dovonex Sales Forecast ($m), 2010-2022

Figure 7.1 Leading Acne Drugs: Market Shares (%), 2010

Figure 7.2 World Acne Drug Market Forecast ($m), 2010-2022

Figure 7.3 Leading Acne Drugs: Sales Forecasts ($m), 2010-2022

Figure 7.4 Leading Acne Drugs: Market Share Forecasts (%), 2010-2022

Figure 7.5 Claravis Sales Forecast ($m), 2010-2022

Figure 7.6 Solodyn Sales Forecast ($m), 2010-2022

Figure 7.7 Diane Sales Forecast ($m), 2010-2022

Figure 7.8 Duac Sales Forecast ($m), 2010-2022

Figure 7.9 Doryx Sales Forecast ($m), 2010-2022

Figure 7.10 Differin Sales Forecast ($m), 2010-2022

Figure 8.1 World Miscellaneous Dermatological Drugs Market: Sales Forecast ($m), 2010-2022

Figure 8.2 Propecia Sales Forecast ($m), 2010-2022

Figure 9.1 Companies in the Dermatological Drug Sector: Market Shares (%), 2010

Figure 11.1 Leading National Markets: Revenue Shares (%), 2010

Figure 11.2 Dermatological Drug Sales Forecasts for US and Japanese Markets ($m), 2010-2022

Figure 11.3 Dermatological Drug Sales Forecasts for Leading European, Indian and Chinese Markets ($m), 2010-2022

Figure 11.4 US: Sales Forecast ($m), 2010-2022

Figure 11.5 Japan: Sales Forecast ($m), 2010-2022

Figure 11.6 Germany: Sales Forecast ($m), 2010-2022

Figure 11.7 France: Sales Forecast ($m), 2010-2022

Figure 11.8 UK: Sales Forecast ($m), 2010-2022

Figure 11.9 Italy: Sales Forecast ($m), 2010-2022

Figure 11.10 Spain: Sales Forecast ($m), 2010-2022

Figure 11.11 India: Sales Forecast ($m), 2010-2022

Figure 11.12 China: Sales Forecast ($m), 2010-2022

Companies Listed

3SBio

Abbott Laboratories

Actavis

Actelion Pharmaceuticals

Albert Einstein College of Medicine

Allergan

Almirall

Altana

American Academy of Dermatology

Amgen

Anacor Pharmaceuticals

AndroScience Corp

AnGesMG

Anterios

Antigenics

Apotex

Apotheca

Applied Genetics

aRigen Pharmaceuticals

Astellas Pharma

Astion

Asubio Pharma

Aurobindo Pharma

Barr

Basilea

Bayer

Bio3 Research

BioCryst Pharmaceuticals

BioMAS

Biomed Research & Technologies

Biotest

Biovail

Birken

Braintree Laboratories

Bristol-Myers Squibb

British Association of Dermatologists

Can-Fite Biopharma

Celgene Corporation

Centocor Ortho Biotech

Cipher Pharmaceuticals

CollaGenex Pharmaceuticals

Cosmo Pharmaceuticals

Creabilis Therapeutics

Critical Therapeutics

Cytotech Labs

DAVA Pharmaceuticals

DeNova Research

Derma Sciences

Dow Pharmaceutical Sciences

Dr. Reddy's Laboratories

DUSA Pharmaceuticals

Eisai

Eli Lilly

Epiphany

European Medicines Agency (EMEA/EMA)

Foamix

Food and Drug Administration (US FDA)

Forward Pharma

Fougera

G&W Labs

Galderma

Gene Signal International

Genzyme

GlaxoSmithKline (GSK)

Glenmark

Graceway Pharmaceuticals

Gruenenthal

Hanwha Pharmaceutical

Hetero Drugs

Immune Control

Immune Control

Immune Technologies & Medicine GmbH

Impax Laboratories

Incyte Corporation

Inhibitex

iNova Pharmaceuticals

INSERM

Intendis

Isotechnika Pharma

Jannsen Biotech

Janssen-Cilag

Johnson & Johnson (J&J)

Kaken Pharmaceutical

KV Pharmaceuticals

Kythera Biopharmaceuticals

L.A.L. Clinica Pesquisa e Desenvolvimento

Laboratorio Teuto Brasiliero

Laboratorios Goulart

LEO Pharma

Ligand Pharmaceuticals

L'Oreal

Lupin

Maruho Co.

Matrix Laboratories

Mayne

Meda AB

Medicines and Healthcare Products Regulatory Agency (MHRA, UK)

Medicis

Medimetriks

Medivir AB

Merck & Co.

Merz Pharmaceuticals

Mitos Pharmaceuticals

Mitsubishi Tanabe

Moberg Derma

Mochida Pharmaceutical Co.

Morria

Mount Sinai School of Medicine

Mycenax Biotech

Mylan

NanoBio Corporation

Nanodermatology Society

National Cancer Institute (US)

National Health Service (NHS, UK)

National Institute for Health and Clinical Excellence (NICE, UK)

National Institute of Allergy and Infectious Diseases (NIAID, US)

Nestle

Nitric Biotherapeutics

Northwestern University

Novartis

Nycomed

Onset Therapeutics

Oplon-Pure Science

Orient Pharma

Ortho Dermatologics

OSI Pharmaceuticals

Par Pharmaceuticals

Paratek

Perrigo

Pfizer

PhotoCure

Pliva

Provectus Pharmaceuticals

QuatRx Pharmaceuticals

Rabin Medical Centre

Ranbaxy

Regeneron Pharmaceuticals

Roche

Roxane Laboratories

Sandoz (part of Novartis)

Sanofi

Schering-Plough

Senetek

Serentis

Sheba Medical Centre

Shinogi

SkinMedica

Sol-Gel

Star Pharma

Stiefel

Summit

Takeda Pharmaceuticals

Taro Pharmaceutical Industries

Teva Pharmaceutical Industries

Tolmar

Tufts Medical Center

University of British Columbia

University of California

Valeant Pharmaceuticals

Vascular Biogenic

Vicept

Visonac

Warner Chilcott

Watson Laboratories

Welichem Biotech

Zalicus

Zurita Laboratorio Farmaceutico

To order this report:

Drug and Medication Industry : Dermatological Drugs: World Market Prospects 2012-2022

More Market Research Report

Check our Industry Analysis and Insights

__________________________

Contact Nicolas: nbo@reportlinker.com

US: (805)-652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker
COPYRIGHT 2012 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 2, 2012
Words:5230
Previous Article:BT Global Services Positioned in the Leaders Quadrant for Three Network Service Provider Magic Quadrants.
Next Article:SkyPeople Fruit Juice, Inc. Appoints Mr. Xin Ma as Chief Financial Officer.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters